Industry: Biotechnology

Sector: Healthcare

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19, COPD, and osteoarthritis. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

Organicell Regenerative Medicine, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.